Related Experiment Video
Updated: Feb 15, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Role of immunotherapy in bladder cancer: past, present and future
Sabeeh-Ur-Rehman Butt1, Laeeq Malik2,3
1Department of Medical Oncology, The Canberra Hospital, Garran, ACT, 2605, Australia. sabeeh.butt@act.gov.au.
Abstract:
As research focus in oncology has recently shifted from oral targeted therapy to immunomodulation, the era of successful drug development in bladder cancer has just begun. This has led to unprecedented approval of five immunotherapeutic agents by regulatory agencies for metastatic bladder cancer within a span of 12 months. With an initial triumph of anti-programmed cell death-1 (anti-PD-1) and anti-programmed cell death ligand-1 (anti-PDL-1) drugs, ongoing efforts are aimed at identification and validation of new druggable immune targets to consolidate the initial gains. In this paper, we review the role of immunotherapy in the treatment of bladder cancer as well as the various emerging immunotherapeutic agents and their possible use in bladder cancer.
Insights
Bladder cancer treatment is advancing with immunotherapy, including new drugs targeting immune responses. Research is exploring novel immunotherapeutic agents to improve patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Urologic Oncology
Background:
- Oncology research is shifting towards immunomodulation for cancer treatment.
- Bladder cancer treatment has seen significant advancements with immunotherapy.
Purpose of the Study:
- To review the role of immunotherapy in bladder cancer treatment.
- To discuss emerging immunotherapeutic agents for bladder cancer.
Main Methods:
- Literature review of recent advancements in bladder cancer immunotherapy.
- Analysis of approved immunotherapeutic agents and ongoing research.
Main Results:
- Five immunotherapeutic agents have been approved for metastatic bladder cancer.
- Anti-programmed cell death-1 (anti-PD-1) and anti-programmed cell death ligand-1 (anti-PDL-1) therapies have shown initial success.
Conclusions:
- The field of bladder cancer immunotherapy is rapidly evolving.
- Identification and validation of new immune targets are crucial for future treatments.
Related Concept Videos
Tumor Immunotherapy
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Anatomy of the Genitourinary System II: Bladder and Urethra
Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
The Role of Culture
Role-Based Identity

